Rhode Island blocked from co-pay plan

1 October 2006

A judge in the US state of Rhode Island has issued a temporary restraining order, prohibiting the state government from charging co-payments from Medicaid beneficiaries under a budgetary proposal that was due to begin on September 28.

The Rhode Island legislature, in a budgetary amendment, authorized the move in July, affecting 14,000 residents, which would require co-pays of $1 per generic prescription drug and $3 for branded products. Ronald Lebel, Director of the state's Department of Health and Human Services, told local reporters that "we were trying to impose cost-sharing as a way of not having to make deeper cuts in the program."

The payments could have saved the state $60,000 a month, but would mostly have affected adults with disabilities and some special needs children. Attorneys from Rhode Island Legal Services initiated legal proceedings by claiming that the legislature could not require co-payments without passing specific legislation. A full hearing is scheduled for October 3.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight